Catalyst Dossier · compiled by CeliA 🧫

SUPERNUS PHARMACEUTICALS, INC. (SUPN)

Pharmaceutical Preparations · market cap $2.6B · as of 2026-06-30

Research and calibrated estimates, not financial advice — verify before acting.

Next catalyst

2026-08-04

Earnings

Pipeline

programs

Upcoming events

next 90d+

Dossier

Ready

cached

Supernus Pharmaceuticals (SUPN) is a commercial-stage CNS-focused specialty pharma company with $719M in 2025 revenue and a pipeline concentrated in ADHD, epilepsy, and neuropsychiatric disorders. The company carries net cash of $184.9M against a $2.7B market cap, with a near-term binary hinging on a Phase 3 readout for SPN-812 (viloxazine extended-release, multiple doses) expected around September 2026. Despite profitable years in 2022 and 2024, the company posted a $39M net loss in 2025, flagging rising costs or commercial headwinds.

The catalyst path

2026-08-04Earningsimp 5/10
2026-09-15 (est.)Phase 3 · SPN-812imp 9/10
2026-10-15 (est.)Phase 2 · SPN-817imp 7/10
2026-12-30 (est.)Phase 2 · BIS-001ERimp 7/10
2026-12-31 (est.)Phase 2 · SPN-821 2400 mgimp 7/10

Pipeline

Asset	Phase	Indication
TPM XR	Phase 2	Epilepsy
400mg SPN-812	Phase 3	ADHD
SPN-810 (36 mg)	Phase 3	Attention Deficit Hyperactivity Disorder (ADHD)
SPN-812	Phase 3	Attention-Deficit/Hyperactivity Disorder
200mg SPN-812	Phase 3	ADHD
2400mg SPN-804	Phase 3	Epilepsies, Partial
SAGE-718	Phase 2	Alzheimer Disease
Molindone	Phase 2	Impulsive Aggression Comorbid With ADHD in Children
BIS-001ER	Phase 2	Focal Impaired Awareness Seizures
MYOBLOC	Phase 3	Sialorrhea
SPN-817	Phase 2	Focal Onset Seizures
IR Viloxazine	Phase 2	Attention-Deficit/Hyperactivity Disorder (ADHD)
Oxcarbazepine XR	Phase 3	Partial Epilepsy
SAGE-547 90 μg/kg/h	Phase 3	Postpartum Depression
SAGE-547 60 μg/kg/h	Phase 3	Postpartum Depression
SPN-810	Phase 2	Attention Deficit Disorder With Hyperactivity
SPN-810 (18 mg)	Phase 3	Attention Deficit Hyperactivity Disorder (ADHD)
Brexanolone	Phase 3	Tinnitus
100mg SPN-812	Phase 3	Attention-Deficit/Hyperactivity Disorder (ADHD)
SAGE-547	Phase 3	Postpartum Depression

Price & technical context

3-month

-6.6%

6-month

-3.7%

12-month

+50.3%

52-wk range

$31.45–$57.00

vs 50-day MA

+1.6%

vs 200-day MA

-2.0%

Realized vol

47.0%

Max drawdown

-24.3%

Daily closes through 2026-07-02. Realized vol annualized; max drawdown over ~2 years.

The full dossier is a Pro feature

Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.

See Pro

Sources & data

SEC filings — EDGAR filings for SUPN (10-K, 10-Q, S-3, 13D/G, Form 4)
Clinical trials — 20 registered trials on ClinicalTrials.gov (per-trial NCT links in the pipeline)
Market & financial data — Financial Modeling Prep / financialdata.net — prices, statements, key metrics, insider & institutional filings.
Regulatory — openFDA, FDA advisory & PDUFA calendars.

Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.

Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, Financial Modeling Prep). Compiled by CeliA. Not financial advice.